Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.67 |
| ▸ | CA2 | P00918 | 15/20 | 0.67 |
| ▸ | CA9 | Q16790 | 13/20 | 0.67 |
| ▸ | CA12 | O43570 | 4/20 | 0.67 |
| ▸ | CA7 | P43166 | 4/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.67 |
| ▸ | CA3 | P07451 | 3/20 | 0.67 |
| ▸ | CA4 | P22748 | 3/20 | 0.67 |
| ▸ | CA6 | P23280 | 3/20 | 0.67 |
| ▸ | CA5A | P35218 | 3/20 | 0.67 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364864 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9097777 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL456239 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5718521 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1459889 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10725960 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5710133 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL185576 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL17336074 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 | |
| SCHEMBL44522 | 1.00 | CA1 (0.67) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015191686-A1 | METHODS OF ADMINISTERING METHYLNALTREXONE | SALIX PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | SALIX PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230149389-A1 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-05-18 | — | — | US | disclosed |
| EP-4142727-A1 | METHODS OF REDUCING MORTALITY RISK IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | Bausch Health Ireland Limited (IE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022260433-A1 | ORGANIC LAYER POLISHING COMPOSITION AND METHOD FOR POLISHING USING SAME | 주식회사 동진쎄미켐 | 2022-12-15 | — | — | WO | disclosed |
| US-20220175764-A1 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-06-09 | — | — | US | disclosed |
| WO-2021224138-A1 | METHODS OF REDUCING MORTALITY RISK IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | BAUSCH HEALTH IRELAND LIMITED (IE) | 2021-11-11 | — | — | WO | disclosed |
| EP-3178472-B1 | ORAL FORMULATIONS OF METHYLNALTREXONE | WYETH LLC (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-107308125-B | Oral formulations and lipophilic salts of methylnaltrexone | 惠氏有限责任公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210121456-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | SALIX PHARMACEUTICALS, INC. (US) | 2021-04-29 | — | — | US | disclosed |
| US-8956651-B2 | Oral formulations and lipophilic salts of methylnal trexone | WYETH, LLC (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2793888-A1 | METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE | Salix Pharmaceuticals, Ltd. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140249171-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20130330407-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2013-12-12 | — | — | US | disclosed |
| US-20130317050-A1 | METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE | MEDICIS PHARMACEUTICAL CORPORATION | 2013-11-28 | — | — | US | disclosed |
| US-8524276-B2 | Oral formulations and lipophilic salts of methylnaltrexone | WYETH, LLC (US) | 2013-09-03 | — | — | US | disclosed |
| WO-2013096444-A1 | METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE | SALIX PHARMACEUTICALS, LTD. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH LLC (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2371357-A1 | Oral formulations and lipophilic salts of methylnaltrexone | Wyeth LLC (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011112816-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | CA1 3999/4885CA2 3378/4885CA9 3764/4885 |
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | MTNR1A, OPRL1, OPRK1 | CA1 2143/4885CA2 2836/4885CA9 2604/4885 |
| US-20140249171-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | CA1 3999/4885CA2 3378/4885CA9 3764/4885 |
| US-20230149389-A1 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | SLC10A2, OPRL1, OGFR | CA1 1744/4885CA2 911/4885CA9 3200/4885 |
| US-20220175764-A1 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | SLC10A2, SLC10A1, NR1H4 | CA1 4733/4885CA2 3899/4885CA9 3874/4885 |
| US-20130317050-A1 | METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE | OPRK1, OPRM1, OPRL1 | CA1 2489/4885CA2 2498/4885CA9 2846/4885 |
| US-20210121456-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | MTNR1A, OPRL1, OPRK1 | CA1 2143/4885CA2 2836/4885CA9 2604/4885 |
| US-20130330407-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | CA1 3999/4885CA2 3378/4885CA9 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.